PMID- 32229214
OWN - NLM
STAT- MEDLINE
DCOM- 20210308
LR  - 20210308
IS  - 1879-0003 (Electronic)
IS  - 0141-8130 (Linking)
VI  - 155
DP  - 2020 Jul 15
TI  - Isolation, structural characterization of polysaccharide from Cephalosporium 
      sinensis mycelia and its anti-nephritic effects in adenine-induced CKD rats.
PG  - 340-349
LID - S0141-8130(20)32781-1 [pii]
LID - 10.1016/j.ijbiomac.2020.03.195 [doi]
AB  - In this study, a new polysaccharide (CSMP, Mw = 16,685 Da) was isolated and 
      purified from Cephalosporium sinensis mycelia. Monosaccharide composition 
      analysis indicated that CSMP consists of mannose, glucose and galactose. A 
      detailed structural analysis revealed that CSMP has a backbone consisting of 
      -->2,6)-beta-D-Manp-(1--> and -->3,6)-beta-D-Manp-(1-->, as well as two branched chains 
      including of alpha-D-Manp-(1-->6)-alpha-D-Glcp-(1--> and 
      alpha-D-Glcp-(1-->4)-alpha-D-Glcp-(1-->3)-beta-D-Galp-(1-->2)-beta-D-Manp-(1--> attached to C6 of 
      -->2,6)-beta-D-Manp-(1--> and -->3,6)-beta-D-Manp-(1-->. Orally administrated CSMP showed renal 
      protection function in adenine-induced chronic kidney disease (CKD) rats. Further 
      analysis demonstrated that CSMP increased relative abundance of the genera 
      Lactobacillus group, Clostridium coccoides group and Bifidobacterium, and 
      decreased Echerichia subgroup. CSMP increased acetate, propionate and butyrate 
      levels both in colon and cecum. The mechanisms behind these effects could be 
      related to the down-regulation nuclear factor kappa-B (NF-kappaB) level by 
      up-regulating expression of G protein-coupled receptor 41 (GPR41) and improvement 
      regulatory T cells (Tregs) ratio by inhibiting histone deacetylase (HDAC) 
      activity. These results indicated that CSMP could be developed as one of the 
      potential drugs in the treatment of CKD.
CI  - Copyright (c) 2020. Published by Elsevier B.V.
FAU - Zha, Zhengqi
AU  - Zha Z
AD  - College of Life Science and Technology, China Pharmaceutical University, Nanjing 
      210009, China.
FAU - Zhang, Zhijie
AU  - Zhang Z
AD  - College of Life Science and Technology, China Pharmaceutical University, Nanjing 
      210009, China.
FAU - Wei, Weikun
AU  - Wei W
AD  - College of Life Science and Technology, China Pharmaceutical University, Nanjing 
      210009, China.
FAU - Nie, Wenbing
AU  - Nie W
AD  - College of Life Science and Technology, China Pharmaceutical University, Nanjing 
      210009, China.
FAU - Chu, Weihua
AU  - Chu W
AD  - College of Life Science and Technology, China Pharmaceutical University, Nanjing 
      210009, China.
FAU - Huang, Fengjie
AU  - Huang F
AD  - College of Life Science and Technology, China Pharmaceutical University, Nanjing 
      210009, China.
FAU - Yue, Long
AU  - Yue L
AD  - College of Engineering, China Pharmaceutical University, Nanjing 210009, China.
FAU - Wang, Su-Yan
AU  - Wang SY
AD  - College of Life Science and Technology, China Pharmaceutical University, Nanjing 
      210009, China.
FAU - Yin, Hongping
AU  - Yin H
AD  - College of Life Science and Technology, China Pharmaceutical University, Nanjing 
      210009, China. Electronic address: yinhongping63@163.com.
LA  - eng
PT  - Journal Article
DEP - 20200327
PL  - Netherlands
TA  - Int J Biol Macromol
JT  - International journal of biological macromolecules
JID - 7909578
RN  - 0 (Polysaccharides)
RN  - IY9XDZ35W2 (Glucose)
RN  - JAC85A2161 (Adenine)
RN  - PHA4727WTP (Mannose)
RN  - X2RN3Q8DNE (Galactose)
SB  - IM
MH  - Acremonium/*chemistry
MH  - Adenine/adverse effects
MH  - Animals
MH  - Galactose/analysis
MH  - Glucose/analysis
MH  - Male
MH  - Mannose/analysis
MH  - Mycelium/chemistry
MH  - Polysaccharides/*chemistry/isolation & purification/pharmacology/therapeutic use
MH  - Rats
MH  - Rats, Wistar
MH  - Renal Insufficiency, Chronic/chemically induced/*drug therapy
OTO - NOTNLM
OT  - Cephalosporium sinensis mycelia polysaccharide
OT  - Chronic kidney disease
OT  - G protein-coupled receptor
OT  - Histone deacetylase
OT  - Short-chain fatty acid
COIS- Declaration of competing interest The authors confirm that there are no conflicts 
      of interest.
EDAT- 2020/04/02 06:00
MHDA- 2021/03/09 06:00
CRDT- 2020/04/02 06:00
PHST- 2019/12/14 00:00 [received]
PHST- 2020/03/04 00:00 [revised]
PHST- 2020/03/22 00:00 [accepted]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2021/03/09 06:00 [medline]
PHST- 2020/04/02 06:00 [entrez]
AID - S0141-8130(20)32781-1 [pii]
AID - 10.1016/j.ijbiomac.2020.03.195 [doi]
PST - ppublish
SO  - Int J Biol Macromol. 2020 Jul 15;155:340-349. doi: 
      10.1016/j.ijbiomac.2020.03.195. Epub 2020 Mar 27.